Understanding The Variation In Frontotemporal Dementia
Funder
National Health and Medical Research Council
Funding Amount
$417,750.00
Summary
Frontotemporal dementia (FTD) is one of the non-Alzheimer dementias which accounts for between 12 and 20% of all dementia and as much as 50% of early onset dementia. It is characterised by marked behavioural change and thus patients with this disease present a major management challenge. The cause of FTD is unknown and at present there is no effective treatment for the disease. There are a number of different clinical subtypes of FTD, namely behavioural variant, language variant, and FTD with mo ....Frontotemporal dementia (FTD) is one of the non-Alzheimer dementias which accounts for between 12 and 20% of all dementia and as much as 50% of early onset dementia. It is characterised by marked behavioural change and thus patients with this disease present a major management challenge. The cause of FTD is unknown and at present there is no effective treatment for the disease. There are a number of different clinical subtypes of FTD, namely behavioural variant, language variant, and FTD with motor neuron disease (FTD+MND). Similarly there are pathological subtypes of FTD (Pick's disease, frontotemporal lobar degeneration and FTD with ubiquitin-positive MND inclusions). However, there appears to be little correspondence between these two subdivisions. The purpose of this study is to investigate the pathological differences and similarities between the different clinical subtypes of FTD. Furthermore, we will investigate the changes in brain atrophy which occur over the course of the disease to allow us to understand better the initial focus of the disease. We will also evaluate the role of cellular protein changes (ubiquitin and tau) in the pathogenesis of neuronal death. This research will allow us (i) to better diagnose and characterise FTD and (ii) establish any common mechanisms of neurodegeneration in the subtypes of FTD.Read moreRead less
GENETIC FACTORS AND REGIONAL BRAIN ATROPHY IN THE DIAGNOSIS OF DEMENTIA WITH LEWY BODIES
Funder
National Health and Medical Research Council
Funding Amount
$605,151.00
Summary
The number of people with dementia is increasing in Australia as people live longer. Dementia sometimes has a genetic basis and identification of such cases has improved our understanding of the events leading to the destruction of the brain tissue. In the vast majority of people, the degenerative changes were previously thought to be as a result of Alzheimer's disease. However, our recent research, funded by the NHMRC, confirms international findings showing more than 25% of people with dementi ....The number of people with dementia is increasing in Australia as people live longer. Dementia sometimes has a genetic basis and identification of such cases has improved our understanding of the events leading to the destruction of the brain tissue. In the vast majority of people, the degenerative changes were previously thought to be as a result of Alzheimer's disease. However, our recent research, funded by the NHMRC, confirms international findings showing more than 25% of people with dementia have a different disease called Dementia with Lewy bodies or DLB. Of course identifying these patients occurs at death when the cells in the brain can be examined for Lewy bodies. We now know that the brain degeneration differs significantly in patients with this disease. However, it is still not possible to identify DLB in life with any certainty. This project aims to develop objective methods to clinically differentiate dementia patients. We will seek out families in which genetic influences may underly the disease and determine whether these factors differ from those found in other dementing illnesses. Also, our preliminary studies have observed volume loss in a particular brain region in pathologically confirmed DLB patients. We wish to do further measurements to determine if tissue loss in this region can clinically differentiate DLB patients. In addition, we will determine the reasons for the tissue loss by careful pathological studies.Read moreRead less